GeoPolitics Pulse

The Heartbeat of World events

Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the …

by ·

The approval encompasses the treatment of Age-Related Neovascular (wet) Macular Degeneration (nAMD) and other serious retinal diseases such as …Read More

Related posts:

  1. European Commission approves aflibercept biosimilar OPUVIZ (previously SB15) from …
  2. Bevacizumab Biosimilar Receives Approval in the European Union – OncLive
  3. The CHMP issues positive opinion for the marketing authorization of FYB203
  4. EU Leads in Biosimilar Market Access While US Lags Behind, Faces Challenges in Adoption
  5. The Biosimilar Revolution: Assessing the European Union’s Approach to … – Cureus